


Healthcare | Large Cap
Dr Reddys Laboratories Ltd presents a strong but mixed financial profile. The company's key strengths are its exceptional profitability and a very secure financial structure with extremely low debt. It consistently generates high returns from its operations and for its shareholders. This financial stability is a significant positive. However, there are substantial concerns regarding its operational efficiency. The company appears to be slow in selling inventory and collecting payments, and it is not using its assets effectively to generate sales. Furthermore, while the company is growing its revenue and assets, this growth has not translated into increased profits, with recent trends showing a decline in earnings. The future outlook depends on leveraging its strong financial base to address these operational inefficiencies.
Dr Reddys Laboratories Ltd presents a strong but mixed financial profile. The company's key strengths are its exceptional profitability and a very secure financial structure with extremely low debt. It consistently generates high returns from its operations and for its shareholders. This financial stability is a significant positive. However, there are substantial concerns regarding its operational efficiency. The company appears to be slow in selling inventory and collecting payments, and it is not using its assets effectively to generate sales. Furthermore, while the company is growing its revenue and assets, this growth has not translated into increased profits, with recent trends showing a decline in earnings. The future outlook depends on leveraging its strong financial base to address these operational inefficiencies.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
32.00
Industry Median
32.52
Large Cap Median
31.40
P/E RATIO
24.56
P/B RATIO
2.72
Industry Median
3.37
Large Cap Median
5.30
P/S RATIO
3.20
Industry Median
3.64
Large Cap Median
5.73
Others
PEG RATIO
0.00
EV/EBITDA RATIO
13.52
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹1234.5 as on Jul 13, 2026.
The company's growth story is one of contrasts. On one hand, it is successfully expanding its business, as shown by strong growth in revenue and its asset base. This suggests market penetration and investment in future capacity. However, this expansion comes at a cost, as growth in profits and earnings per share has been negative. This concerning trend indicates that rising costs or pricing pressures are eroding profitability, and the company is not yet effectively converting its top-line growth into bottom-line value.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 13.11 | 14.5 | 13.54 | 16.54 | 3.23 |
| Operating Profit Growth Rate | -2.74 | 71.71 | 22.61 | 7.74 | -24.49 |
| Earnings Per Share (EPS) Growth | 11.76 | 106.4 | 23.51 | 1.35 | -25.82 |
| Asset Growth Rate | 11.88 | 8.28 | 20.4 | 23.83 | 21.03 |
| Net Income Growth Rate | 11.78 | 106.55 | 23.76 | 2.64 | -27.37 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Abbott India Ltd | 8.68 | 37.51 | Neutral | 1892.00 | 730.39 | 1552.00 |
| 2 | Glaxosmithkline Pharmaceuticals Ltd | 8.38 | 39.58 | Neutral | 1309.00 | 59.73 | 1036.00 |
| 3 | Alkem Laboratories Ltd | 8.08 | 28.92 | Neutral | 3005.00 | 182.76 | 2351.00 |
| 4 | Lupin Ltd | 7.84 | 21.37 | Neutral | 8816.00 | 139.24 | 5355.00 |
| 5 | Cipla Ltd | 7.62 | 29.71 | Neutral | 5883.00 | 43.51 | 3862.00 |
| 6 | Mankind Pharma Ltd | 7.61 | 54.11 | Overvalued | 3617.00 | 49.34 | 1938.00 |
| 7 | Zydus Lifesciences Ltd | 7.60 | 22.59 | Neutral | 8475.00 | 35.69 | 5124.00 |
| 8 | Laurus Labs Ltd | 7.10 | 94.69 | Neutral | 1778.00 | 13.71 | 890.00 |
| 9 | Dr Reddys Laboratories Ltd | 6.68 | 24.56 | Neutral | 6454.00 | 38.57 | 4158.00 |
| 10 | Glenmark Pharmaceuticals Ltd | 6.36 | 47.69 | Neutral | 4572.00 | -7.12 | 1362.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Concall Report⬤3rd Jul 26
Q4 FY26 Earnings Conference Call
BULLISH SENTIMENT
Annual Report⬤2nd Jul 26
Annual Report 2025-26
UNDEFINED SENTIMENT
Concall Report⬤2nd Jul 26
Q4 FY26 Earnings Conference Call
BULLISH SENTIMENT
Concall Report⬤2nd Jul 26
Q4 FY26 Earnings Conference Call
BULLISH SENTIMENT